Latest Product Launch News

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.

AoFrio Limited has initiated a 1-for-7 renounceable rights offer at NZ$0.07 per share aiming to raise nearly NZ$5 million. This follows a recent $4.56 million placement and supports an aggressive growth strategy targeting $300 million revenue by 2030.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Champion Iron Limited reported a 19% increase in net profit to C$168.7 million for FY2026, driven by record production and sales, progress on its DRPF project, and the strategic acquisition of Rana Gruber.

AoFrio Limited is offering existing shareholders a 1-for-7 rights issue at NZ$0.07 per share following a NZ$4.56 million placement, aiming to raise nearly NZ$5 million to fund growth ambitions.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

Knosys has locked in a two-year, $3.8 million contract extension with ANZ, with full payment received upfront. This deal underpins Knosys’s role in ANZ’s AI integration efforts and strengthens the company’s cash position.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Aroa Biosurgery posted a breakout FY26, beating revenue and EBITDA guidance with a 54% surge in Myriad sales. The company plans significant investments in FY27 to accelerate growth and capitalise on new market opportunities.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.

Plenti Group Limited (ASX:PLT) has smashed its $3 billion loan portfolio target two months ahead of schedule, delivering a 117% surge in cash profit before tax to $30.8 million for FY26. The fintech lender’s growth was fuelled by record loan originations, robust credit performance, and strategic technology investments.

James Hardie Industries saw a 25% sales increase in FY26 driven by the AZEK acquisition but reported a 75% net income decline amid acquisition costs and margin pressures. The company expects synergy gains and adjusted EBITDA growth in FY27.